Dr. Gregory K. Behbehani, M.D., PH.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 80
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2005Medical school: University of Cincinnati College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.126934 -
Hematology & Oncology Physician
CA license A104260 -
Internal Medicine Physician
CA license A104260
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 335
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 116 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Idhifa (enasidenib mesylate) | 32 |
| Venclexta (venetoclax) | 25 |
| Tibsovo (ivosidenib) | 21 |
| Xospata (gilteritinib fumarate) | 20 |
| Hydroxyurea Other prescribers in Columbus, OH | 19 |
| Ondansetron Hcl Other prescribers in Columbus, OH | 18 |
| Imatinib Mesylate | 14 |
| Acyclovir Other prescribers in Columbus, OH | 14 |
| Bosulif (bosutinib) | 12 |
| Inqovi (decitabine/cedazuridine) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $1,321 in total to this clinician.
| Adaptive Biotechnologies Corporation | $1,197 |
|---|---|
| Jazz Pharmaceuticals Inc. | $124 |
| Travel and Lodging | $1,197 |
|---|---|
| Food and Beverage | $124 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adaptive Biotechnologies Corporation Feb 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Seattle, WA | $606 |
| Adaptive Biotechnologies Corporation Feb 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Seattle, WA | $576 |
| Adaptive Biotechnologies Corporation Feb 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Seattle, WA | $9.00 |
| Adaptive Biotechnologies Corporation Feb 5, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Seattle, WA | $6.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $271,588 in research payments for these studies, mostly to the institutions running them.
- First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi US Services Inc. · Terminated · NCT05086315 - Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin Chemotherapy
Jazz Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.